LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Strona główna・Stock List・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Closed

SectorHealthcare

3.92 0.26

Buy Sell

Overview

Share price change

24h

Current

Min

3.8

Max

3.99

Key metrics
By Trading Economics
Income	-21M 41M
Sales	59M 107M
P/E Sector Avg	6.323 50.102
EPS	0.24
Profit margin	38.282
Employees	100
EBITDA	64M 73M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+27.55% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-110M 645M
Previous open	3.66
Previous close	3.92

News Sentiment

By Acuity

93%

3 / 344 Ranking in Healthcare

Ironwood Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 maj 2026, 16:52 UTC

Major News Events

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 maj 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q Rev $1.76B >SQM

26 maj 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q EPS $1.28 >SQM

26 maj 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 maj 2026, 21:54 UTC

Earnings

Webco Industries 3Q EPS $11.61 >WEBC

26 maj 2026, 21:54 UTC

Earnings

Webco Industries 3Q Sales $179.6M >WEBC

26 maj 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 maj 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 maj 2026, 20:58 UTC

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 maj 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 maj 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 maj 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 maj 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 maj 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 maj 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 maj 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 maj 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 maj 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 maj 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 maj 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 maj 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

26 maj 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 maj 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 maj 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Comparison

Price change

Ironwood Pharmaceuticals Inc Forecast

Price Target

By TipRanks

27.55% upside

12 Months Forecast

Average 5 USD 27.55%

High 5 USD

Low 5 USD

Based on 2 Wall Street analysts offering 12 month price targets forIronwood Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Ironwood Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

3 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.